1 million lives saved by MMV co-developed medicines since 2009

18,000 health-care workers across 2,082 health-care facilities trained to administer injectable artesunate for severe malaria, via CHAI and the Malaria Consortium in the MMV-led Improving Severe Malaria Outcomes (ISMO) funded by UNITAID

75 million vials of Artesun® (Guilin Pharma’s injectable artesunate) delivered to treat children with severe malaria, saving an estimated additional 450,000–500,000 lives compared to quinine treatment 

>90% of severe malaria patients now receive treatment with injectable artesunate instead of quinine across 6 countries through the MMV-led ISMO project

Cipla’s rectal artesunate suppository received a 12-month authorization from the Global Fund for procurement of their suppositories for pre-referral management of severe malaria, with MMV’s support

73 million courses of SP+AQ were shipped to countries in the Sahel of West Africa in 2016, by MMV's partner Guilin Pharmaceutical, enough to provide 18 million children with Seasonal Malaria Chemoprotection

New medicine for children, Pyramax® granules (pyronaridine-artesunate), co-developed with Shin Poong, added to the WHO list of prequalified medicines

First potential new medicine for relapsing malaria in more than 60 years, tafenoquine, completes phase III trials with GSK

MMV048 progresses to phase IIa as new formulation with 4x greater exposure identified 

180 Pathogen Boxes shipped free of charge to scientists around the world to boost neglected diseases drug discovery

9 potential new medicines in clinical development prioritizing treatment for vulnerable populations and supporting malaria eradication

1 donor dollar creates an estimated 3.5 dollars of investment impact thanks to direct and in-kind support from partners

12,000 episodes of malaria in almost 5,000 patients assessed in first trial investigating the real-life safety and effectiveness of four ACTs (WANECAM) – data provides reassurance of safety when re-dosing patients with the same drug